Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pulmonx (LUNG) EBIT Margin (2019 - 2025)

Pulmonx has reported EBIT Margin over the past 7 years, most recently at 66.94% for Q3 2025.

  • Quarterly EBIT Margin rose 237.0% to 66.94% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 62.38% through Sep 2025, up 1102.0% year-over-year, with the annual reading at 68.87% for FY2024, 2132.0% up from the prior year.
  • EBIT Margin was 66.94% for Q3 2025 at Pulmonx, down from 62.05% in the prior quarter.
  • Over five years, EBIT Margin peaked at 56.46% in Q4 2024 and troughed at 145.28% in Q1 2022.
  • The 5-year median for EBIT Margin is 85.9% (2023), against an average of 88.82%.
  • The largest YoY upside for EBIT Margin was 20988bps in 2021 against a maximum downside of -6433bps in 2021.
  • A 5-year view of EBIT Margin shows it stood at 90.21% in 2021, then fell by -5bps to 94.83% in 2022, then grew by 24bps to 72.2% in 2023, then rose by 22bps to 56.46% in 2024, then decreased by -19bps to 66.94% in 2025.
  • Per Business Quant, the three most recent readings for LUNG's EBIT Margin are 66.94% (Q3 2025), 62.05% (Q2 2025), and 64.62% (Q1 2025).